Moderna, Inc. (MRNA)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 142 | 108 | 1,862 | 241 |
| Research and development | 700 | 856 | 1,137 | 1,221 |
| Selling, general and administrative | 230 | 212 | 281 | 268 |
| Cost of sales | 119 | 90 | 514 | 115 |
| Total operating expenses | 1,049 | 1,158 | 1,932 | 1,604 |
| Loss from operations | -907 | -1,050 | -70 | -1,363 |
| Interest income | 81 | 90 | 103 | 111 |
| Other income (expense), net | 8 | -4 | -12 | -27 |
| Loss before income taxes | -818 | -964 | 21 | -1,279 |
| Provision for income taxes | 7 | 7 | 8 | - |
| Net loss | -825 | -971 | 13 | -1,279 |
| Basic (in shares) | 388,000,000 | 386,000,000 | 385,000,000 | 384,000,000 |
| Basic (in usd per share) | -2.13 | -2.52 | 0.03 | -3.33 |
| Diluted (in shares) | 388,000,000 | 386,000,000 | 399,000,000 | 384,000,000 |
| Diluted (in usd per share) | -2.13 | -2.52 | 0.03 | -3.33 |